Fuzhou General Hospital
52
2
3
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
3.8%
2 terminated/withdrawn out of 52 trials
85.7%
-0.8% vs industry average
4%
2 trials in Phase 3/4
0%
0 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (52)
Posterior Extra-fascial RARP in Intermediate or High Risk Prostate Cancer
Role: collaborator
Therapy for Advanced NSCLC With EGFR 19delins Mutation
Role: lead
Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC
Role: lead
SERS-Based Serum Molecular Spectral Screening for Benign and Malignant Pulmonary Proliferative Nodules
Role: lead
SERS-Based Serum Molecular Spectral Screening for Lung Cancer Type
Role: lead
SERS-Based Serum Molecular Spectral Screening for Hematogenous Metastasis
Role: lead
SERS Sensor Based on CHA Reaction for EGFR Mutation Typing in Advanced Lung Cancer
Role: lead
SERS-Based Serum Molecular Spectral Detection of Invasive Lung Cancer
Role: lead
QYJD Compound Preparation Promotes Rapid Postoperative Recovery in Early-stage NSCLC Patients by Regulating Tissue Microecology: a Prospective, Randomized Controlled, Open-label, Phase I Clinical Study With Predefined Future Exploration
Role: lead
Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma
Role: lead
Registry of IgA Nephropathy in Chinese Children
Role: collaborator
MSC and MC in Type 2 Diabetes Mellitus
Role: lead
The Efficacy and Safety of Azovudine in the Treatment of COVID-19
Role: lead
Defining COVID-19 Infection Severity on Presentation to Hospital
Role: lead
Application of Endoscopic Scissors Cutting ENBD Tube in the Treatment of Malignant Hilar Biliary Strictures
Role: collaborator
ctDNA as a Biomarker for Treatment in Advanced NSCLC
Role: lead
Peginterferon Alpha-2b Therapy in Chronic Hepatitis Patients With Normal ALT Level and Low Viremia
Role: lead
Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC
Role: lead
Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.
Role: lead
Camrelizumab Combined With Radiotherapy for Adjuvant Treatment of Esophageal Squamous Cell Carcinoma After Surgery
Role: lead